Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 10, 2026European Heart Journal

GPVI-targeting drugs show potential as safe antithrombotics by blocking GPVI-mediated platelet activation.

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Key result

GPVI-targeting drug candidates (Revacept, Glenzocimab, EMA601) offer potential as safe antithrombotic therapies by blocking collagen-binding sites or GPVI-mediated platelet activation.

Authors

JMJames D. McFadyenXWXiaowei WangKPKarlheinz Peter

Discussion

Loading...

Member takes

Overview

GPVI-targeted agents merit phase 3 evaluation; leaves open net clinical benefit versus current antiplatelets.

Key Points

  • This research aims to explore the potential of GPVI as a safer target for antithrombotic therapy while minimizing bleeding risks.
  • Examined various GPVI-targeting drug candidates: Revacept, Glenzocimab, and EMA601.
  • Evaluated the mechanisms of action related to platelet activation and collagen binding.
  • Discussed efficacy in reducing bleeding risk compared to traditional antithrombotic treatments.
  • Revacept effectively blocks collagen-binding sites on GPVI, potentially reducing thrombus formation.
  • Glenzocimab significantly inhibits GPVI-mediated platelet activation.
  • EMA601 partially retains platelet adhesion but prevents full activation, offering a balance between safety and efficacy.

Structured PICO

I
Intervention
GPVI-targeting drug candidates (Revacept, Glenzocimab, EMA601)

GPVI-targeted therapies represent a novel class of antithrombotics that may decouple antithrombotic efficacy from bleeding risk.

Cite This Study

McFadyen et al. (2024) conducted a review in Thrombosis. GPVI-targeting drug candidates (Revacept, Glenzocimab, EMA601) was evaluated. GPVI-targeting drug candidates (Revacept, Glenzocimab, EMA601) offer potential as safe antithrombotic therapies by blocking collagen-binding sites or GPVI-mediated platelet activation.

synapsesocial.com/papers/6a5161ccf86e72888e9b6711https://doi.org/10.1093/eurheartj/ehae592
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Relieving platelet inhibition using a novel bi-specific antibody: A novel approach for circumventing the platelet storage lesion2025
  2. 2Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy2026
  3. 3Blocking FcγRIII with anti-CD16 mab (3G8 and GMA161) increases platelets in immune thrombocytopenia: Two pilot studies2025
  4. 4Platelet Rubicon Bidirectional Regulation of GPVI and Integrin αIIbβ3 Signaling Mitigates Stroke Infarction Without Compromising Hemostasis2026
  5. 5Developing an AI-Generated Peptide Targeting Platelet-type von Willebrand Disease2025